default author photo

COVID-19 Early Treatment Study Team Group

Independent

United States

SCHOLARLY PAPERS

2

DOWNLOADS

233

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

Hydroxychloroquine with or Without Azithromycin for Treatment of Early SARS-CoV-2 Infection Among High-Risk Outpatient Adults: A Randomized Clinical Trial

Number of pages: 43 Posted: 09 Dec 2020
University of Washington, University of Washington - Vaccine and Infectious Disease Division, Division of Allergy and Infectious Diseases, University of Washington, University of Washington - Division of Allergy and Infectious Diseases, School of Public Health and Tropical Medicine, Tulane University, School of Medicine, Tulane University, John H. Stroger, Jr., Hospital of Cook County, John H. Stroger, Jr., Hospital of Cook County, Boston University School of Medicine, Walter Reed Army Institute of Research - Clinical Trials Center, Department of Global Health, University of Washington, Department of Global Health, University of Washington, Department of Global Health, University of Washington, Vaccine and Infectious Disease Division, University of Washington, New York University (NYU) - Grossman School of Medicine, Division of Cardiology, University of Washington, Division of Cardiology, University of Washington, Mayo Clinic, Mayo Clinic, Department of Global Health, University of Washington, Department of Laboratory Medicine and Pathology, University of Washington, University of Washington - Department of Laboratory Medicine and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington, University of Washington - Department of Medicine, Fred Hutchinson Cancer Research Center - Clinical Research Division, University of Washington - Department of Global Health, University of Washington - Division of Allergy and Infectious Diseases, Division of Allergy and Infectious Diseases, University of Washington, University of Washington - Department of Global Health and Independent
Downloads 131 (554,631)
Citation 2

Abstract:

Loading...

coronavirus, COVID-19, SARS-CoV-2, hydroxychloroquine, azithromycin, early treatment, remote enrollment, randomized controlled trial

2.

Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials

TLRHEUROPE-D-24-00554, https://doi.org/10.2139/ssrn.4901222
Number of pages: 19 Posted: 07 Aug 2024
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University College London - Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Division of Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Catholic University of Milan, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department, University of Rome Tor Vergata, Sapienza University of Rome, Sapienza University of Rome, University of Udine, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Università Cattolica del Sacro Cuore, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Translational Research Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata, Sapienza University of Rome - Department of Public Health and Infectious Diseases, University of Rome Tor Vergata - Faculty of Medicine and Surgery, Magna Graecia University of Catanzaro - Department of Medical and Surgical Sciences, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Laboratory of Virology, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department and Independent
Downloads 102 (679,608)

Abstract:

Loading...

COVID-19, early treatment, outpatients, fragile populations